Background: Although ankle-brachial index (ABI) and brachial-ankle pulse wave
| INTRODUCTION
End-stage kidney disease (ESKD) is characterized by multiple risk factors which pose increased risks of mortality and major adverse cardiovascular events (MACE). 1, 2 The mechanisms underlying the association between ESKD and MACE include highly prevalent comorbidities such as coronary artery disease, cerebrovascular disease, and peripheral artery disease (PAD). [2] [3] [4] Accumulating evidence suggests that arterial stiffness and anklebrachial index (ABI) are well correlated with atherosclerotic burden and are strong predictors of MACE. [5] [6] [7] [8] Among the various indices of arterial stiffness, brachial-ankle (ba) pulse wave velocity (PWV) is an established tool for the noninvasive assessment of arterial stiffness in clinical practice. 9, 10 However, measurements of baPWV can be influenced by the presence of PAD and hemodynamic condition after hemodialysis (HD) session. [11] [12] [13] Therefore, the prognostic value of baPWV in ESKD patients is still discussed. 14 With the widespread clinical application of standardized assays, several biomarkers and multiple biomarker approach enable the accurate prediction of the long-term prognosis of ESKD patients treated with HD. [15] [16] [17] Previous studies have demonstrated that cardiac troponin (cTn), brain-natriuretic peptide (BNP), and C-reactive protein (CRP) are the robust predictors of MACE independent of traditional risk factors and two-dimensional thoracic Doppler echocardiography (TTDE) findings. [18] [19] [20] [21] However, the prognostic significance of ABI/PWV in association with biomarkers have not been fully investigated in ESKD patients. In addition, the heterogeneous risks of ESKD patients might require risk assessment approach from multiple aspects. The aim of this study was to investigate the prognostic value of ABI/PWV in association with biomarkers and to examine whether biomarkers would provide additional predictive value on ABI/PWV in ESKD patients treated with HD.
| METHODS

| Study population
During the period between April 2012 and February 2013, a total of 104 consecutive ESKD patients treated with HD for more than 1 year at the Ishikiri-seiki Hospital were enrolled in this study. The exclusion criteria were as follows: (a) patients who were hospitalized within the past 1 month due to acute coronary syndrome (ACS) or heart failure;
(b) patients with systemic infection or chronic inflammatory diseases;
and (c) patients with symptomatic severe valvular heart diseases requiring surgical intervention. The present study was approved by the Ethics Committee of Ishikiri-seiki Hospital and was conducted in accordance with the institutional regulations and the Declaration of Helsinki. All the study patients gave written informed consent for the enrollment in this study.
| Laboratory data collection
All the patients were required to provide baseline plasma samples before HD session on the day underwent HD session, including hemoglobin, hemoglobin A1c, cholesterol profiles, BNP, high-sensitive cTnT (hs-cTnT), and high-sensitive CRP (hs-CRP). The samples were centrifuged within 60 minutes and stored at −80 C for further analysis. hs-cTnT was measured by an electro chemiluminescence immunoassay (ECLIA) with the EClusys hs-cTnT Roche diagnostic assay. In the hs-cTnT assay, the 99th percentile of the upper reference limit and the lower limit of detection were 0.014 and 0.003 ng/mL, respectively. BNP was measured with a specific immunoradiometric assay for human BNP (ARCHITECT BNP-JP; ABBOTT JAPAN Co, Ltd, Tokyo, Japan). The inter-and total coefficient variation for BNP was 1.1% to 5.1% and 2.3% to 5.3%, respectively. Hs-CRP was measured using N-latex CRP II (Dade Behring Inc., Marburg, Germany) with a coefficient variation of 3.1% at 0.5 mg/L.
| ABI/PWV and TTDE examinations
ABI/PWV and TTDE examinations were performed in all study patients in our laboratory at appropriate temperature according to the guideline. over the surface of the body. ABI was calculated as the ratio of the systolic blood pressure measured at the ankle to that at the brachial artery, with no blood access. The lower value of ankle blood pressure was used for the assessment of ABI. Abnormal ABI was defined as <0.90 or >1.40. 6 TTDE examination was also performed after the HD session at the study enrollment using a commercially available system (the Vivid 7; General Electric, Milwaukee, Wisconsin) by trained cardiac echo sonographers. Left ventricular ejection fraction (LVEF) was calculated by using Simpson method from apical 4-and 2-chamber views, as previously reported. 21 In the present study, LVEF <50% was defined as decreased LVEF. 3 | RESULTS
| Outcome assessment
| Patient characteristics and outcomes
Baseline patient characteristics are presented in Table 1 . The mean age of the entire group was 71 ± 7 years, 63% were male (n = 66), and For the normal ABI group, all-cause death, ACS requiring coronary revascularization, and stroke were observed in 22, 3, and 5 patients, respectively.
| Prognostic value of biomarkers and noninvasive examinations
In the entire group, univariate Cox hazard analysis showed that age >75 years (HR, 2.13; P = .012), abnormal ABI (HR, 2.42; P = .002), LVEF <50% (HR, 3.27; P = .002), upper tertile of hs-cTnT (HR, 3.12; P < .001), upper tertile of hs-CRP (HR, 1.99; P = .016), and upper tertile of BNP (HR, 1.90; P = .024) were the statistically significant predictors of MACE. Borderline significance was observed in the upper tertile of baPWV (HR, 1.68; P = .068). However, other variables were not associated with MACE. In multivariable model, age >75 years (HR, 2.15; P = .017), abnormal ABI (HR, 2.01; P = .020), LVEF <50% (HR, 3.33; P < .001), upper tertile of hs-cTnT (HR, 2.77; P = .022), and upper tertile of hs-CRP (HR, 1.96; P = .022) remained as the independent predictors of MACE (Table 2) .
Similarly, univariate and multivariable Cox hazard analysis were performed to investigate the prognostic value of baPWV in the normal ABI group (Table 3) . In univariate analysis, statistically significant predictors of MACE were age >75 years (HR, 3.33; P = .002), LVEF Prior myocardial infarction, n (%) 10 (10) Prior coronary revascularization, n (%) 29 (28) Prior stroke, n (%) 15 (14) Smoking history, n (%) 35 (34)
Systolic blood pressure, mm Hg 138 ± 22
Heart rate, bpm 75 ± 12 LVEF <50%, n (%) 20 (19) baPWV, cm/s 2262 ± 748
Abnormal ABI, n (%) 31 ( all-cause mortality, and cardiovascular events in ESKD patients. 12 Several studies have reported that multiple-biomarker approach enabled to provide better risk stratification of ESKD patients. [15] [16] [17] [18] [19] [20] In consistent with the previous studies, we observed that upper tertile of hsTnT and hs-CRP are independently associated with MACE for the overall population of ESKD. However, the prognostic value of ABI/-PWV in association with biomarkers has not been fully investigated in ESKD patients.
In the present study, we found that abnormal ABI was a strong predictor of MACE independent of biomarkers, whereas baPWV was not an independent predictor for the entire group and also for the patients with normal ABI. baPWV has been reported to be correlated with the direct measure of aortic PWV and carotid-femoral PWV, which has been shown to be a strong predictor of mortality in ESKD Note: The outcome measures of baPWV and biomarkers including BNP, hs-cTnT, and hs-CRP were divided into tertiles of the entire group (n = 104). Abbreviations: ABI, ankle-brachial index; ba-PWV, brachial-ankle-pulse wave velocity; BNP, brain-natriuretic protein; CI, confidence interval; HR, hazard ratio; hs-CRP, high-sensitive C-reactive protein; hs-cTnT, high-sensitive cardiac troponin T; hs-TnT, high-sensitive troponin T; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular event; PWV, pulse wave velocity.
T A B L E 3 Cox hazard analysis to predict MACE in the normal ABI group (n = 73) Note: The outcome measures of baPWV and biomarkers were divided into tertiles of the normal ABI group (ABI between ≥0.9 and ≤1.4; n = 73). Abbreviations: ABI, ankle-brachial index; ba-PWV, brachial-ankle-pulse wave velocity; BNP, brain-natriuretic protein; CI, confidence interval; HR, hazard ratio; hs-TnT, high-sensitive troponin T; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular event; PWV, pulse wave velocity.
patients. 10, 23 However, because of technical issues such as measurement protocols and reproducibility, 22 the use of baPWV for the accurate risk prediction of ESKD patients is still discussed. 14 Ho-Ming, et al showed that the ba-PWV measurements were influenced by blood volume changes after HD sessions, whereas ABI was not.
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These observations support the use of ABI for the risk stratification of ESKD patients treated with HD.
Furthermore, we found that the combination of upper tertile of hs-cTnT or hs-CRP in addition to abnormal ABI showed higher risk compared to abnormal ABI alone. A possible explanation is that elevations of these biomarkers represent the target organ damage and systemic inflammation, which is difficult to be evaluated by ABI alone.
Abnormal ABI has been shown to be well correlated with systemic disease burden of atherosclerosis, which is a strong predictor of MACE. 6, 8 On the other hand, accumulating evidence demonstrated that an elevation of cTn is specific to myocardial damage [24] [25] [26] and hs-CRP reflects systematic atherosclerotic burden and activity even in ESKD patients. 1, 17, 27 As multiple organ disorder causes markedly higher systemic adverse events, 2-4 these observations suggest that biomarker approach complements the risk assessment that cannot be identified by ABI alone, and their combination could provide better risk stratification of ESKD patients treated with HD.
In addition, we observed that decreased LVEF remained as an independent predictor of MACE in both the entire group and the nor- 
| STUDY LIMITATIONS
Our study has several limitations. First, this study included relatively small number of patients with and without normal ABI. Our findings regarding the predictors of MACE should be interpreted with caution, although baPWV did not remain as an independent predictor of MACE even in the normal ABI group. Second, we employed baPWV as a marker of arterial stiffness because of its common use in clinical practice. Different markers such as aortic stiffness and arterial stiffness gradient to assess arterial stiffness may contribute to the prediction of MACE in association with biomarkers and other noninvasive tests. 7 Finally, we evaluated the markers at a single time point of the study enrollment. Arterial stiffness is associated with organ damage which cannot be entirely explained by the established cardiovascular risk factors. 32 Several studies have suggested the potential benefit to assess changes in arterial stiffness as the treatment response. Future studies are needed to investigate the impact of targeting changes in arterial stiffness after optimized therapy in predicting MACE in ESKD patients.
| CONCLUSIONS
This study demonstrated that abnormal ABI was a robust predictor of MACE independent of biomarkers and decreased LVEF, whereas ba-PWV was not. The combination of the presence or absence of these predictors could provide better risk stratification compared with abnormal ABI alone in ESKD patients treated with HD.
